Diabetes Research and Clinical Practice · 2024 · Tập 212 · 111691
DOI Trang nguồn Toàn văn RIS BibTeX
Tóm tắt
AIMS: This study aims to investigate the trends in treatment coverage through dispensing diabetes medications in Vietnam from 2015 to 2021. The findings will serve to inform health policies to mitigate the health burden of Type 2 diabetes mellitus (T2DM). METHODS: We collected information on major antidiabetic medicines from General Department of Vietnam Customs and payments for antidiabetics via the National Health Insurance Program. We applied ordinary least squares models, accounting for economic and health outcome characteristics, to estimate the association between the annual mass of medications and related factors. RESULTS: Nationally, the total mass/doses of all antidiabetic drugs increased rapidly from 2015 to 2021, based on both databases. Metformin was the most frequently prescribed medicine, with the total mass increasing nearly threefold over the study period. Gliclazide, a Sulfonylureas drug, ranked second. In the multivariate regression analysis, a one-unit increase in adults with diabetes (in 1,000 s) was associated with 0.11 % (95 %CI = 0.0005; 0.0076) and 0.13 % (95%CI = 0.0007; 0.0242) higher mass of Metformin and Glimepiride, respectively. CONCLUSION: Our data suggested that policies changes were related to significant increase in antidiabetic medication dispenses in Vietnam. The high treatment coverage indicates impressive progress in achieving universal health coverage in Vietnam, meeting the UN Sustainable Development Goal (SDG).
Nguyên văn tóm tắt của bài gốc đăng trên Diabetes Research and Clinical Practice.
Thông tin công bố
| Loại tài liệu | Bài báo tạp chí |
|---|---|
| Truy cập | Toàn văn truy cập mở đã xác minh |
| Giấy phép | https://www.elsevier.com/tdm/userlicense/1.0/ |
| Mã HERAC | HERAC-MEM-2024-015 |
Thông tin thư mục do HERAC biên tập và đối chiếu với trang nguồn. Vui lòng đọc và trích dẫn tài liệu gốc.